JBIO (Jade Biosciences, Inc.) Stock Financials & Earnings

JBIOJade Biosciences, Inc.

Mkt Cap$491M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$127M

EPS (TTM)-$5.46

Free Cash Flow (TTM)-$104M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Next: Q1 2026 · Mar 26

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q3 23	$0	-$25K	-$21M
Q4 23	$0	-$28K	-$22M
Q1 24	$0	-$28K	-$25M
Q2 24	$0	-$28K	-$26M
Q3 24	$0	$0	-$15M
Q4 24	$0	-$8K	-$6M
Q1 25	$0	-$4K	-$3M
Q2 25	$0	-$1K	-$28M
Q3 25	$0	-$12K	-$27M
Q4 25	$0	$0	-$35M

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q3 23	$17M	—	$4M
Q4 23	$18M	—	$4M
Q1 24	$20M	—	$5M
Q2 24	$21M	—	$5M
Q3 24	$14M	—	$1M
Q4 24	$2M	—	$5M
Q1 25	—	—	$3M
Q2 25	$23M	$5M	—
Q3 25	$22M	—	$5M
Q4 25	$29M	—	$6M

War Chest

Quarter	Cash	Short-term Investments	Total
Q3 23	$32M	$103M	$135M
Q4 23	$23M	$99M	$122M
Q1 24	$9M	$90M	$99M
Q2 24	$31M	$73M	$104M
Q3 24	$31M	$58M	$89M
Q4 24	$34M	$45M	$79M
Q1 25	$44M	$32M	$76M
Q2 25	$221M	$0	$221M
Q3 25	$50M	$149M	$199M
Q4 25	$0	$248M	$248M

Shares Outstanding